Hypothesis

Aged intestinal epithelial dysfunction stems from a deficit in microbiota‑derived indole‑3‑propionic acid (IPA) that fails to activate pregnane X receptor (PXR) at physiological concentrations (5‑10 µM). Restoring luminal IPA to this range in aged mice will reinstate PXR‑driven chromatin accessibility at the Muc2 and tight‑junction loci, thereby thickening the mucus layer and sealing barrier defects without invoking the anti‑inflammatory AhR pathway or exacerbating xenobiotic detoxification programs. This effect will be absent in PXR‑deficient (Nr1i2−/−) aged mice, proving causality and microbiome dependence.

Rationale

• Mechanistic gap: Prior work shows IPA‑PXR signaling upregulates B3galt5 and tight‑junction proteins in young colitis or diabetic models, but never tests whether the same axis operates in the senescence‑associated barrier decline characterized by reduced mucus thickness and leaky epithelia (see 2).
• Ligand specificity: IPA exhibits a concentration‑dependent switch: 1‑10 µM favors AhR‑mediated immune modulation, whereas >50 µM drives PXR activation (see 1). Physiological fecal IPA in young mice is 2‑6 µM; aging correlates with a drop to <1 µM, placing the ligand in a range where AhR may dominate but PXR remains sub‑threshold. We posit that selective PXR activation at the upper end of the physiological window (5‑10 µM) can be achieved in aged gut by overcoming microbial depletion, and that this concentration avoids AhR‑driven immune skewing.
• Epigenetic angle: Aging is associated with increased histone deacetylase (HDAC) activity at mucin promoters, suppressing Muc2 transcription. Preliminary data indicate that PXR can recruit co‑activators (SRC‑1, p300) that antagonize HDAC3 at xenobiotic response elements. We hypothesize that ligand‑bound PXR in aged enterocytes displaces HDAC3 from the Muc2 enhancer, increasing H3K27ac and RNA polymerase II occupancy, thereby restoring mucus synthesis.

Experimental Plan

Model system

• Animals: Young (3 mo) and aged (20‑24 mo) C57BL/6J mice, Nr1i2−/− (PXR KO) littermates, and germ‑free (GF) counterparts.
• Interventions: Oral gavage of IPA at 5 µM (physiological low) vs. 50 µM (supraphysiological) vs. vehicle, daily for 2 weeks. Include a group receiving Clostridium sporogenes (IPA‑producing) versus a non‑producing mutant.

Readouts

1. Barrier function: FITC‑dextran (4 kDa) serum flux, transepithelial electrical resistance (TER) in Ussing chambers, mucus thickness ( confocal microscopy of MUC2‑stained colon).
2. Molecular: qPCR/Western for ZO‑1, occludin, claudin‑1, MUC2; ChIP‑seq for PXR, HDAC3, H3K27ac at Muc2 promoter/enhancer; RNA‑seq to delineate aging‑specific PXR transcriptional signature vs. young IBD signature.
3. Microbiome verification: 16S rRNA sequencing to confirm colonization status; LC‑MS quantification of luminal IPA.
4. Control for AhR: Measure CYP1A1 expression and IL‑22 levels to ensure low‑dose IPA does not significantly activate AhR.

Predictions

• If hypothesis is true: Aged WT mice receiving 5‑10 µM IPA (or C. sporogenes colonization) will show mucus thickness comparable to young controls (~28 µm), reduced FITC‑dextran flux, and increased TER, accompanied by PXR occupancy at the Muc2 locus, loss of HDAC3 binding, and elevated H3K27ac. These improvements will be absent in Nr1i2−/− aged mice and in GF aged mice not colonized with an IPA‑producer.
• If hypothesis is false: IPA restoration will fail to improve barrier metrics in aged WT mice, or improvements will persist in PXR‑KO animals, indicating either a PXR‑independent mechanism or that IPA depletion is merely correlative.

Falsifiability

A clear falsifiable outcome is the lack of significant barrier rescue (p > 0.05 vs. vehicle) in aged WT mice treated with physiological IPA despite confirmed luminal IPA levels of 5‑10 µM and intact PXR expression. Conversely, rescue in Nr1i2−/− mice would refute the necessity of PXR.

Broader Impact

Confirming that a defined microbial metabolite can epigenetically reinstate gut barrier integrity in aging would shift focus from broad anti‑inflammatory strategies to precise metabolite‑receptor epigenetics, informing probiotic or prebiotic interventions aimed at mitigating age‑related inflammaging.